These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31253631)

  • 1. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.
    Kamran SC; Lennerz JK; Margolis CA; Liu D; Reardon B; Wankowicz SA; Van Seventer EE; Tracy A; Wo JY; Carter SL; Willers H; Corcoran RB; Hong TS; Van Allen EM
    Clin Cancer Res; 2019 Sep; 25(18):5561-5571. PubMed ID: 31253631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
    Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
    Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy.
    Yang J; Lin Y; Huang Y; Jin J; Zou S; Zhang X; Li H; Feng T; Chen J; Zuo Z; Zheng J; Li Y; Gao G; Wu C; Tan W; Lin D
    Theranostics; 2019; 9(23):6856-6866. PubMed ID: 31660073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
    Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
    Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
    Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
    Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
    Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.
    Wilkins A; Fontana E; Nyamundanda G; Ragulan C; Patil Y; Mansfield D; Kingston J; Errington-Mais F; Bottomley D; von Loga K; Bye H; Carter P; Tinkler-Hundal E; Noshirwani A; Downs J; Dillon M; Demaria S; Sebag-Montefiore D; Harrington K; West N; Melcher A; Sadanandam A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33678606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
    Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
    PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response.
    Lee TH; Jang BS; Chang JH; Kim E; Park JH; Chie EK
    Cancer Med; 2023 Jul; 12(14):15664-15675. PubMed ID: 37260182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
    Mouw KW; Cleary JM; Reardon B; Pike J; Braunstein LZ; Kim J; Amin-Mansour A; Miao D; Damish A; Chin J; Ott PA; Fuchs CS; Martin NE; Getz G; Carter S; Mamon HJ; Hornick JL; Van Allen EM; D'Andrea AD
    Clin Cancer Res; 2017 Jun; 23(12):3214-3222. PubMed ID: 27852700
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
    Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
    Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
    Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
    J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
    Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
    PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
    Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions.
    Sakai K; Kazama S; Nagai Y; Murono K; Tanaka T; Ishihara S; Sunami E; Tomida S; Nishio K; Watanabe T
    Oncotarget; 2014 Oct; 5(20):9641-9. PubMed ID: 25275295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy.
    Chang YK; Tseng HH; Leung CM; Lu KC; Tsai KW
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling.
    Liu H; Zhang Z; Zhen P; Zhou M
    J Immunol Res; 2021; 2021():6657012. PubMed ID: 33506057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.